IDO1 and hepatocellular carcinoma: ICI resistance originates from an IFN-γ-mediated increase in IDO in anti-CTLA-4-treated HCC cells and can be reversed by the IDO inhibitor 1-methyl-d-tryptophan (1-d-MT), as demonstrated in animal experiments [91].